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Abstract. The treatment of advanced-stage oropharyngeal 
squamous cell carcinoma may utilize various modes, including 
combining surgery with chemoradiotherapy (CTRT), or 
primary CTRT followed by rescue surgery. In previous litera-
ture it has been revealed how patients treated with combined 
modes report a low quality of life (QoL) and severe conse-
quences following surgery, radiotherapy and chemotherapy, 
in the short and in the long-term. The decrease in the QoL 
of patients treated with high-intensity multi-modal strategies 
highlights the necessity of modifying treatments, particularly 
for young HPV-positive patients, where an increased survival 
rate has already been reported. The modified treatment for 
HPV-positive tumors in the tonsils and at the base of the 
tongue is based on the deintensification of therapies aiming 
to reduce toxicity and thereby improve QoL in the long term, 
whilst still maintaining therapeutic effectiveness. The aim of 
the present study was to evaluate the QoL in patients with a 
long-term survival, who were treated with combined therapy 
for squamous cell tumors in the tonsils and at the base of the 
tongue, and to compare the results observed in HPV-positive 
and HPV-negative patients. According to statistical analysis, 
differences in the general QoL and in the single scales of the 
European Organization for the Research and Treatment of 
Cancer questionnaires were not correlated with the type of 
therapy selected for the particular patient. QoL considered the 
presence of HPV, the type of treatment, the subregion of the 
tonsils vs. the base of the tongue and the disease stage at the 
time of diagnosis, and was determined to be non‑influential 
with regard to these specific variables.
Introduction
Squamous cell oropharyngeal carcinoma is a disease with a 
rising incidence in various Western countries (1). This increase 
is primarily due to a high number of human papillomavirus 
(HPV)-associated tumors in the tonsils and at the base of the 
tongue (1,2). It has been established that HPV squamous cell 
cancer has an improved diagnosis and clinical outcomes, as 
compared with HPV-negative tumors (1-3).
Squamous cell cancer in the tonsils and at the base of the 
tongue is often diagnosed in an advanced loco-regional phase, 
which is stage III-IVB (1). Squamous cell carcinoma treatments 
at these stages may use various modes, including combining 
surgery with chemoradiotherapy (CTRT) or primary CTRT 
followed by rescue surgery (4). A review of the literature 
revealed that patients treated with combined modes typically 
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reported a low quality of life (QoL), with severe consequences 
following surgery, radiotherapy and chemotherapy, in the short 
and in the long-term (5,6). The decrease in the QoL of patients 
treated with high-intensity multi-modal strategies highlights 
the necessity of modifying treatments, particularly for young 
HPV-positive patients, where an increased survival rate has 
already been reported. (1,3,7,8). The modified treatment for 
HPV-positive tumors in the tonsils and at the base of the tongue 
is based on the deintensification of current therapies, with the 
aim of reducing toxicity and, therefore, improving long-term 
QoL, whilst also maintaining therapeutic effectiveness (3,9).
To date, few studies have analyzed the QoL for long-term 
survival patients who were treated with combined therapy 
for oropharyngeal squamous cell cancer in the tonsils or at 
the base of the tongue (10). The incidence of oropharyngeal 
squamous cell cancer is increasing in Western countries, by 
contrast with a decrease in the incidence of other types of 
carcinoma in alternate cervicofacial regions, despite a reduced 
smoking prevalence (1). Infection with HPV, particularly HPV 
type 16, is currently considered to be an important factor 
for the insurgency of HPV-positive oropharyngeal carci-
nomas, which exhibit various radiological, epidemiological, 
clinical, anatomical, biological and prognostic features, when 
compared with HPV-negative carcinomas (3,11). The only 
region in the cervicofacial area with a demonstrated viral etio-
logical connection is the oropharynx (3,8). These studies raise 
certain questions about the choice of therapy and the intensity 
of treatment that should be used depending on the stage of the 
HPV tumor (12,13).
The aim of the present study was to evaluate the QoL of 
patients with a long-term survival, who were treated with 
combined therapy for squamous cell tumors in the tonsils and 
at the base of the tongue, and then to compare the QoL results 
reported by patients who were HPV-positive and HPV-negative. 
As HPV is associated with an improved response to treatment 
and a greater survival time, it was hypothesized that patients 
with HPV-high-risk (HR)-associated oropharyngeal squamous 
cell carcinoma may have an improved QoL. Understanding 
the association between the HPV status and the post-treatment 
QoL may improve the management of patients with squamous 
cell HPV-HR-associated carcinoma and potentially enable the 
development of personalized therapy, in order to optimize not 
only the survival rate, but also the QoL for each patient.
Materials and methods
Patients. The present study involved multicenter research, 
as the patients were recruited and attended follow-ups at 
either the Ear, Nose and Throat (ENT) Department of the 
University of Trieste (Trieste, Italy), the ENT Unit of Treviso 
Hospital (Treviso, Italy), University of Padua (Padua, Italy), 
the Interhospital ENT Department of the Province of Venice 
(Venice, Italy) or the ENT Department of the University of 
Catania (Catania, Italy).
The present cross-sectional study used the following inclu-
sion criteria: The presence of a squamous cell tumor in the 
tonsils or at the base of the tongue at stage III-IVB; patients 
who had not previously been treated for squamous cell tumors 
in the tonsils or at the base of the tongue, regardless of the 
correlation with HPV; treatment that includes surgery alone 
or plus CTRT, or primary CTRT ± rescue surgery; complete 
remission following treatment; treatment was completed 
≥60 months prior to being included in the present study; 
patients who exhibited signs of remission following the 
completion of the questionnaire.
A total of 48 patients, 34 males (71%) and 14 females 
(29%), were recruited for the present study. The age ranged 
between 40-79 years old at the time of diagnosis. All the 
recruited patients signed an informed consent. Among the 
cases collected from the various recruitment centers, each had 
a survival time of ≥5 years following treatment for oropharyn-
geal squamous cell carcinoma; those patients with stage I/II 
disease, with oropharyngeal carcinoma not associated with the 
tonsils or the base of the tongue, or who were not completely 
recovered from the disease were not included. The patient 
clinical features, tumor sub-region, tumor-node-metastasis 
(TMN) grade stage and HPV status are summarized in Table I. 
The number of recruited cases, considering the age at the time 
of diagnosis, is summarized in Table II.
Questionnaires. QoL was evaluated using questionnaires 
prepared by the European Organization for the Research and 
Treatment of Cancer (EORTC), in particular using the general 
questionnaire analyzing QoL: QoL Questionnaire-Core 30 
(QLQ‑C30) and the specific questionnaire for the head and 
neck area (35/QLQ-H&N35) (14,15). These questionnaires 
were completed during follow-up appointments or under 
specific doctor's request, in person or over the phone. The 
results of the QoL questionnaires were analyzed according to 
the specific scoring manual provided by the EORTC (16,17), 
all scores were expressed on a scale ranging between 0-100.
Laboratory examination. For molecular analysis formalin- 
fixed paraffin‑embedded (FFPE) tumor samples were used. 
All tumor samples were tested for the presence of HPV and 
details of the method are already published in Baboci et al (18). 
Briefly, DNA was extracted and amplified through broad 
spectrum L1 multiplex human papillomavirus genotyping 
(BS-L1-MPG assay) (19). In total, ~150 bp for the gene L1 of 
~51 types of mucosal HPV were amplified. Detection of the 
human β-globin gene was used as a control for the quality of 
DNA, as well as a control for polymerase chain reaction (PCR).
The DNA samples were also analyzed using MY09/11-PCR 
amplification, followed by Restriction Fragment Length 
Polymorphism and direct sequencing (20). Additionally, 
the expression of p16 protein was immunohistochemi-
cally analyzed from the same FFPE tumor samples. Due 
to limited sample availability, p16 protein expression was 
analyzed in 29 patients using CINtec® p16INK4a Histology, 
ready-to-use mouse monoclonal antibody (clone E6H4™; cat.
no. 06695248001; Roche Diagnostics, Basel, Switzerland) on 
Automated immunohistochemistry stain Ventana BenchMark 
Ultra (Roche Diagnostics). Sections of tissue (2-4 µm) were 
deparaffinized with Ez‑Prep 1X for 25 min at 72˚C (cat. 
no. 05279771001; Roche Diagnostics). Subsequently, on-board 
heat antigenic retrieval was performed for 36 min at 95˚C in 
Ultra CC1 (Tris-Borate-EDTA pH 8.2; cat. no. 05424569001; 
Roche Diagnostics) (21,22). Slides were left to cool on-board 
by the system for 4±1 min. Endogenous peroxidase enzymes 
were blocked with 3% hydrogen peroxide for 4 min at 36˚C 
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Table I. Clinicopathological characteristics of patients with advanced oropharyngeal carcinoma.
No. Name Gender Age Location Year of diagnosis Treatment TNM Stage HPV
  1 A1 M 71 Bilateral tonsil-base 2008 CTRT+SG  T3N2b IV N
    of the tongue soft palate
  2 A2 M 66 Tonsil-base of the tongue 2008 CTRT+SG T2N2b IV P 
  3 A3 M 64 Tonsil 2005 CTRT+SG T2N1 III P 
  4 A4 M 56 Tonsil 2009 CTRT +SG T2N2b IV P 
  5 A5 M 56 Tonsil-base of the tongue 2007 CTRT+SG T4aN2b IV N
  6 A6 F 57 Tonsil-base of the tongue 2010 CTRT+SG T3N2 IV P
    Trigone-mandible
  7 A7 M 60 Tongue-oropharynx 2004 CTRT+SG T4aN2b IV P
  8 A8 M 57 Tonsil 2008 SG T1N1 III N
  9 A9 M 52 Base of the tongue-Trigone 2010 SG T3N0 III N
10 A10 F 56 Trigone-Tonsil-Bse 2006 CTRT+SG T3N1 III N
    of the tongue
11 A11 F 73 Tonsil 2010 CTRT+SG T2N2b IV P
12 A12 M 68 Tonsil-base of the tongue 2007 CTRT+SG T3N2c IV P
13 B1 F 65 base of the tongue 2006 SG+RT T2N2 IV P
14 B2 M 69 Tonsil 2003 SG+RT T2N2 IV N
15 B3 M 56 Base of the tongue 2006 SG+RT T3N1 III N
16 B4 F 46 Base of the tongue+tongue 2004 SG T2N1 III P
17 B5 M 60 Base of the tongue 2006 SG on head T3N0 III N
      and neck and
      lung+RT
18 B6 M 58 Base of the tongue 2003 CTRT T4N2b IV N
19 B7 F 62 Base of the tongue 2003 SG T2N1 III N
20 B8 M 50 Bilateral tonsil+velum 2002 SG+RT T3N2b IV N
21 B9 F 58 Tonsil 2003 SG+RT T3N2 IV N
22 B10 M 53 Base of the tongue 2000 SG+RT T3N2 IV P
23 B11 F 65 Tonsil 2001 SG T1N1 III N
24 B12 F 65 Tonsil 2000 SG T2N1 III N
25 B13 M 52 Tonsil-base of the tongue 2000 SG+RT T3N2 IV P
26 B14 M 54 Base of the tongue 2000 SG+RT T3N2 IV P
27 B15 M 46 Base of the tongue 2001 SG T1N1 III P
28 B16 M 58 Base of the tongue 2000 SG T2N1 III N
29 B17 M 68 Tonsil 2002 SG T2N1 III N
30 B18 M 71 Tonsil 2007 RT T3N2 IV N
31 B19 M 75 Tonsil 2007 SG+RT T1N2a IV N
32 B20 F 70 Base of the tongue 2007 SG+RT T1N2a IV N
33 B21 M 58 Base of the tongue 2008 SG T1N1 III P
34 B22 M 55 Tonsil (+ 2005,2015) 2008 SG+RT T1N1 III N
35 B23 M 55 Base of the tongue 2009 SG+RT T2N2a IV P
36 B24 M 79 Base of the tongue 2010 CTRT T2N2 IV N
37 B25 F 60 Tonsil 2008 CTRT T2N1 III P
38 B26 M 58 Tonsil 2009 CTRT T4aN2b IV N
39 B27 M 63 Tonsil 2009 CTRT+neck T4N3 IV N
      dissection
40 B28 M 66 Base of the tongue 2010 CTRT+neck T3N2b IV N
      dissection
41 B29 F 40 Tonsil 2008 CTRT+neck T1N2 IV P
      dissection
42 C1 F 68 Left tonsil 2009 CTRT T3N2c IV P 
43 C2 M 60 Tonsil-right base of the tongue 2009 CTRT T4N2b IV P
44 C3 M 64 Tonsil 2004 CTRT T4N0 IV N
45 C4 M 71 Right tonsil 2007 CTRT T1N2b IV N
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(UltraView Universal DAB Inhibitor). The slides were incu-
bated with the CINtec® p16INK4a Histology primary antibody 
for 24 min at 36˚C. Detection was then performed on‑board 
with Ultraview DAB Detection kit (cat. no. 05269806001; 
Roche Diagnostics). UltraView DAB Detection kit 
Universal horseradish peroxidase-conjugated Multimer, 
α-mouse/rabbit secondary antibody was added and incubated 
for 8 min at 36˚C. Subsequently, the signal was revealed with 
a chromogen-substrate solution (DAB plus H2O2; Roche 
Diagnostics) for 8 min at 36˚C, followed by a signal enhancer 
step for 4 min at 36˚C with copper sulfate. Final counterstain 
was performed using hematoxylin. Tissues positive for p16 
were defined by clear and dispersed nuclear and cytoplasmic 
staining in ≥70% of tumor cells. Cervical HPV‑positive tissue 
sections were used as positive controls and negative controls 
were produced by omitting the primary antibody (19).
Statistical analysis. Descriptive statistics were computed for 
all functioning and symptoms scale scores (Table III). A multi-
variate analysis of variance (MANOVA) approach was used to 
determine whether a number of interconnected and dependent 
variables, the scales of the QoL-C30 and those of the H&N35, 
were influenced by the five following independent variables: 
i) HPV positivity (positive vs. negative); the 12 participants 
whose information was unavailable were excluded from the 
analysis that included HPV as a factor. ii) The type of treat-
ment received by the patient (surgery vs. CTRT, vs. surgery 
and RT, vs. surgery and CTRT). It must be acknowledged that, 
concerning the analysis that included the type of treatment 
as an independent variable, no patients who were exclusively 
treated with RT without surgery were included. iii) The stage 
of the disease (III vs. IV); with regards to this predictor, no 
distinction was made between stage IVA and IVB, as only one 
patient was reported to have stage IVB disease. iv) The patient 
gender (male vs. female). v) The age of the patient at the time 
of diagnosis (<60 vs. ≥60 years).
In the prediction of the QLQ-C30 and H&N35 scales, 
the five independent variables were included separately in 
each MANOVA, using the Wilks's λ statistic test (23,24). The 
approximate F distribution was used to evaluate the impact 
of each independent variable with a statistical significance 
threshold of α=0.05. The results of this analysis are reported 
in Table IV. Follow-up analyses were performed using unequal 
variances t-tests (Table V). All analyses were performed using 
R statistical language software (version 3.3.1) (16,17).
Results
Descriptive statistics of patients. A total of 48 patients were 
enrolled and analyzed in the current study, including 71% males 
and 29% females. The age descriptive statistics are reported 
in Table II. When considering the stage of the disease and 
the subregion, 16 patients were determined to have stage III 
disease and 32 patients had stage IV disease. Overall, 46% 
of the cases involved the tonsil region, 40% involved the base 
of the tongue and 14% involved both of the subregions. The 
immunohistochemical data indicated the presence of HPV in 
40% of the patients.
Table III reports the descriptive statistics of the 15 QoL 
C30 scales and of the 18 H&N35 scales. The functioning scale 
with the lowest average score was global QoL (15,16), whereas 
the functioning scale with the highest score was on the cogni-
tive functions scale. The symptom with the highest average 
self-reported score in the QLQ-C30 survey was C30-SL 
(insomnia) (14,16), followed by C30‑FI (financial difficulties) 
and by C30-CO (constipation)  (14,16). In the H&N35 ques-
tionnaire, the symptoms with the highest self-reported scores 
were dry mouth, sticky saliva and use of painkillers (15,16).
Variables associated with HR‑QoL. Table IV reports the 
results of MANOVAs predicting the QLQ-C30 and the 
H&N35 scale scores. In the prediction of the QLQ-C30 scales, 
only one independent variable, the age of the patient at the 
time of the diagnosis, showed a significant effect, whereas 
no variables significantly predicted the H&N35 scales. The 
effect of age was followed-up with several t-tests, reported in 
Table V. Patients who were older than 60 at the time of the 
diagnosis tended to report worse physical functioning, worse 
Table I. Continued.
N. Name Gender Age Location Year of diagnosis Treatment TNM Stage HPV
46 C5 M 49 Base of the tongue 1999 SG+RT T1N2b IV N
47 C6 M 54 Base of the tongue 2003 CTRT T4N1 IV N
48 C7 F 59 Tonsil 2000 CTRT T3N2a IV N
HPV, human papilloma virus; CTRT, chemotherapy-radiotherapy; TNM, tumor-node-metastasis; SG, surgery; P, positive; N, negative.
Table II. Analysis of the cohort of patients with advanced 
oropharyngeal carcinoma with regards to age.
Factor Age, years old
Average patient age  69.74
SD of age 7.83
Min age 46.68
Max age 83.41
Average age at the time of the diagnosis 60.33
SD of age at the time of the diagnosis 8.11
Min age at the time of the diagnosis 40
Max age at the time of the diagnosis 79
SD, standard deviation.
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role functioning, more constipation, and more appetite loss 
compared to patients that were <60 years at the time of diag-
nosis.
Discussion
There are several reasons to change treatment strategies in 
patients affected by HPV-induced OSCC, as the international 
guidelines on the treatment of HPV-associated oropharyn-
geal squamous cell carcinoma are currently the same as 
for non-HPV-associated OSCC. The patients are treated 
with surgery or RT in the early-stages, and with combined 
treatment in the advanced-stages (4). It currently appears 
that the success of the various approaches is similar, and that 
the treatment selection must be made with consideration of 
associated therapeutic morbidities and the long-term 
QoL (25,26).
In the past few decades RT techniques have changed. 
Functional outcomes between Intensity Modulated Radio 
Therapy (IMRT) and standard 2D RT are controversial in the 
literature; however, it is unanimous on the best functional results 
on chewing functioning, swallowing difficulty, taste and xero-
stomia may be better or identical compared with standard 2D 
RT (27,28). The anatomical structures spared by IMRT improve 
Table III. Results of EORTC QLQ C30 and H&N35.
Scale Average Standard deviation Median Range
QLQ-C30
  Global Quality of Life 70.7 26.7 75 0-100
  Physical functioning 82.4 18.1 86.7 33.3-100
  Role functioning 85.8 23.3 100 0-100
  Emotional functioning 80.9 21.6 91.7 16.6-100
  Cognitive functioning 89.2 19 100 16.6-100
  Social functioning 82.3 26.3 100 0-100
  Fatigue 17.8 18.6 11.1 0-66.7
  Nausea and vomiting 1 5.3 0 0-33.3
  Pain 14.2 23.1 0 0-83.3
  Dyspnea 10.4 23 0 0-100
  Insomnia 20.1 26.4 0 0-100
  Appetite loss 9 21.5 0 0-100
  Constipation 18.8 26.5 0 0-100
  Diarrhea 0.7 4.8 0 0-33.3
  Financial difficulties 19.4 30.6 0 0‑100
QLQ-N&H35
  Pain 6.4 11.8 0 0-58.3
  Swallowing 16.6 17.8 12.5 0-66.7
  Sensing problems 18.4 23.6 16.7 0-100
  Speech problems 14.6 17.6 11.1 0-77.8
  Trouble with social eating 12.2 17.9 8.3 0-75
  Trouble with social contact 9.6 17.2 0 0-73.3
  Sexual life 26.7 36.2 0 0-100
  Teeth 31.3 33.3 33.3 0-100
  Opening mouth  12.5 26.3 0 0-100
  Dry mouth 41 39.6 33.3 0-100
  Sticky saliva 31.9 38.3 16.7 0-100
  Coughing 17.4 26.6 0 0-100
  Feeling ill 4.1 14.78 0 0-66.7
  Use of pain killers 31.3 46.8 0 0-100
  Nutritional supplement use 22.9 42.4 0 0-100
  Feeding tube 2.1 14.4 0 0-100
  Weight loss 14.6 35.7 0 0-100
  Weight gain 25 43.8 0 0-100
EORTC, European Organization for the Research and Treatment of Cancer; QLQ C30, quality of life questionnaire‑core 30; H&N35, specific 
questionnaire for the head and neck area.
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long-term effects with regard to swallowing, maintaining a 
local control of the disease. For these reasons, IMRT may be 
considered as a potential standard treatment for oropharyngeal 
carcinoma (28-31). Similarly, in patients treated with surgery in 
the early-stages, a long-term functional improvement may be 
observed, comparable with patients who received adjuvant RT 
following surgery of a primary tumor (31,32).
Some scholars suggest that patients not treated with 
surgery have more problems concerning xerostomia, dental 
problems and taste, as compared with patients treated with 
isolated surgery or followed with adjuvant RT (27,32). When 
comparing the results of the QoL questionnaire completed 
by patients exclusively treated with surgery with those of 
patients who received any type of RT treatment, the latter 
Table IV. GLM-MANOVA test of the effects of the clinical and demographic variables on EORTC QLQ-C30 and H&N35 scales.
A, Dependent variables: QLQ-C30 scales
Variable Wilk's λ F Num df Den df P-value Sample size (n)
HPV 0.662 1.09 15 32.0 0.402 48
Treatment 0.240 1.19 45 86.9 0.239 47
Stage 0.897 0.25 15 32.0 0.997 48
Sex 0.711 0.87 15 32.0 0.605 48
Age group 0.429 2.84 15 32.0 0.007 48
B, Dependent variables: QLQ-H&N35 scales
HPV 0.737 0.57 18 29.0 0.889 48
Treatment 0.275 0.79 54 78.3 0.824 47
Stage 0.744 0.55 18 29 0.904 48
Gender 0.605 1.05 18 29 0.438 48
Age group 0.672 0.79 18 29 0.698 48
Reported models are unifactorial (i.e., a separate MANOVA was performed for each independent variable). All the analyses were performed 
on 48 patients, with the exception of those in which the independent variable was treatment, which were performed on 47 patients. MANOVA, 
multivariate analysis of variance; EORTC, European Organization for the Research and Treatment of Cancer; QLQ-C30, quality of life 
questionnaire‑core 30; H&N35, specific questionnaire for the head and neck area; HPV, human papilloma virus; df, degrees of freedom.
Table V. Follow-up t-tests to evaluate the effect of age on QLQ-C30 scales.
QoL‑C30 scale Average <60 years Average ≥60 years t df P‑value
Overall quality of life 72.9 68.4 0.582 45.657 0.564
Physical functioning 89.2 75.6 2.793 40.939 0.008
Role functioning 93.1 78.5 2.259 33.301 0.031
Emotional functioning 76.7 85.1 -1.348 43.555 0.185
Cognitive functioning 92.4 86.1 1.144 45.995 0.258
Social functioning 79.9 84.7 -0.637 44.086 0.528
Fatigue  16.2 19.4 -0.600 45.191 0.552
Nausea or vomiting 0 2.1 -1.366 23.000 0.185
Pain 11.1 17.4 -0.938 45.814 0.353
Dyspnea 6.9 13.9 -1.049 32.731 0.302
Insomnia 20.8 19.4 0.180 44.288 0.858
Appetite loss 15.3 2.8 2.089 28.216 0.046
Constipation 8.3 29.2 -2.930 37.311 0.006
Diarrhea 0 1.4 -1.000 23.000 0.328
Financial difficulties 20.8 18.1 0.311 42.323 0.757
The analyses were performed on 48 participants. QLQ C30, quality of life questionnaire-core 30 (24); t, t-statistic of the unequal variance t-test; 
df, degrees of freedom.
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complained significantly of xerostomia and dental prob-
lems (29,32,33).
In the present study, 14 cases were treated with surgery 
followed by adjuvant RT; 13 cases were treated with surgery 
followed by CTRT; 10 cases were treated with sole CTRT and 
10 cases were treated exclusively with surgery. According to 
the statistical analysis conducted in the present study, which 
omitted the single case of the patient who was treated exclu-
sively with RT, the differences in general QoL and of the single 
scales that were analyzed are not correlated with the type of 
therapy selected for the treatment of the patient.
In the last three decades, pathological models of head 
and neck squamous carcinomas have changed. In particular, 
the incidence of HPV-associated tumors has increased, as 
compared with tumors associated with alcohol and tobacco 
consumption (1,33,34). It is well known that patients with 
high-risk HPV-associated oropharyngeal cancer have 
increased survival rates, suggesting a high response to 
RT (13). Immunohistochemical analysis of the results 
indicated that the presence of HPV in 40% of the patients 
involved in the present study was consistent with the data 
from the Memorial Sloan Kettering Cancer Center (MSKCC), 
where in 2000 in the USA are described 40% of HPV-induced 
oropharyngeal squamous cell carcinomas. While, the same 
study demonstrated an incidence increase of 60-70% in the 
United States of HPV-associated OSCC between 2010 and 
2014 (1). The study of QoL, conducted by a group from 
the Fred Hutchinson Cancer Research Centre of Seattle 
and Washington, using questionnaires from Washington 
University, demonstrated how patients with high-risk HPV 
in the pre-treatment phase experience an improved QoL, as 
compared with patients with low-risk HPV or HPV-negative 
cases (32). Conversely, immediately following the surgery, the 
same patients with high‑risk HPV reported a more significant 
decrease in QoL, as compared with patients with low-risk 
HPV and with patients who were HPV-negative. One year 
following the treatment, there were no significant differences 
in QoL observed among the patients, when considering the 
stage of HPV (32). These results suggest that a decrease in 
QoL immediately following surgery in patients with high-risk 
HPV may be due to the high intensity of the treatment 
administered in this population (32,35). Deintensification 
of the treatment was suggested for patients with HPV-HR 
oropharyngeal squamous carcinoma, as they are typically 
younger and have an improved survival rate, compared with 
other patients with the same disease (26). The importance of 
determining the stage of HPV in patients with oropharyngeal 
carcinoma may lead to a deintensified therapeutic regiment 
for the patient, in order to optimize survival and QoL trajec-
tories in this population (26).
Currently, standard treatments are also applicable in 
patients who are HPV-positive where robotic transoral surgery 
has revealed the greatest prognosis and functional results, even 
though the most effective therapy for HPV-associated carci-
noma is still under discussion, and trans oral robotic surgery 
(TORS) or surgery associated with RT is able to provide a good 
level of QoL (25). With a combination of TORS and adjuvant 
therapy, the disease may be controlled both in HPV-positive 
and HPV‑negative tumors. In particular, the benefits of this 
type of surgery appear to include good survival rates, allowing 
the reduction of the dose and volume of the following RT, in 
order to reduce long-term toxicity; this characterizes combined 
radical CTRT treatment. (25,26,36).
A number of studies aimed at evaluating the possible 
deintensification of current treatments able to be applied to 
the low-medium risk category of patients are in progress. Such 
deintensification may consist of a reduction of the radiation 
dose and/or alterations of the concomitant therapy; for example, 
avoiding chemotherapy and replacing it with a biological 
therapy, such as cetuximab, and introducing neoadjuvant 
chemotherapy in order to avoid concomitant chemotherapy. At 
this time, there is insufficient data to modify the selection of 
the therapy depending on the risk profile (25,31,37,38).
Furthermore, it is necessary to reflect upon two further 
aspects: The type of laboratory tests conducted in order to 
evaluate the presence of HPV in patients, and the type of ques-
tionnaire provided to determine QoL.
Increasing evidence concerning the diagnostic role of HPV 
HR in oropharyngeal oncology, which is associated with a more 
favourable prognosis and a higher radiosensibility, suggests 
that it is required to identify useful molecular markers, which 
may be integrated into the clinical management of oropharyn-
geal SCC (39). The use of p16 in immunohistochemistry, as 
a marker to determine the presence of HPV, is controversial. 
For certain authors, it may be associated with a high rate of 
false-positive results, increasing the necessity for the identi-
fication of novel markers for the infection of oral HPV (3,9); 
these studies suggest not relying exclusively on p16 for HPV 
screening (3,35). The inconsistency of the methods currently 
used to identify molecular markers in the field of head and 
neck oncology, in particular for HPV infection, is one of the 
primary obstacles faced in clinical practice. For this reason, 
an agreement on the methods used to identify high-risk HPV 
in squamous cell carcinoma in head and neck oncology is 
essential (3,9,19,21,39).
Statistical analysis carried out on the patients involved 
in the current study, considering HPV-positivity to be an 
independent variable, indicated that it has no significant influ-
ence on the final QoL score, as compared with HPV‑negative 
patients. These results appear to be concordant with those of 
the Seattle team study, which stated that one year following 
therapy the patient QoL was not statistically different between 
patients who were HPV-negative and HPV-positive (35). In the 
present study, the results on QoL correlated with HPV is justi-
fied as the patient sample considered had a long‑term survival 
time ≥5 years; there are patients with survival times between 
5-16 years (mean, 9.5 years) following treatment.
The EORTC questionnaire used (14,15), as compared with 
the one proposed by Washington University, is more detailed in 
addressing the various aspects of activity, the body and social 
functions, allowing for a more specific evaluation, particularly 
with regards to swallowing and aspects of global health. The 
EORTC questionnaire is widely used due to its reliability and 
effectiveness (14,15). Currently, there is no questionnaire avail-
able for this particular field that may be universally adopted 
for the improved analysis of variables, and also to interpret 
results with the same parameters.
In conclusion, completing the exposition of the data 
collected in the present study, it was determined that QoL is 
influenced by age in patients with a long‑term survival time 
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who were treated for oropharyngeal carcinoma at the base 
of tongue or in the tonsils. Scrutinizing the age variable with 
several t‑tests, it emerged that patients who were older than ≥60 
at the time of the diagnosis tended to report poorer physical 
functioning (questions 1-5 of the QLQ-C30 questionnaire), 
more severe limits to physical ability (questions 6 and 7 of 
QLQ-C30), more appetite loss (question 13 of QLQ-C30) and 
more constipation (question 16 QLQ-C30), as compared with 
younger patients. Since analyzed cases are taken in consider-
ation from 5-16 years following treatment, and 69-years-old is 
the average age of patients in the present study, the results may 
be influenced by aging.
In conclusion, the available data supports the concept 
that oropharyngeal tumors have been increasing in incidence 
globally over the last 20 years, as compared with other types 
of head and neck-associated tumors, particularly in Western 
countries (1). With respect to the treatment of the disease and 
based on current understanding, HPV-positive oropharyngeal 
cancer may be considered a singular type of cancer in head and 
neck area with relatively favourable outcomes. Patients with 
HPV-positive oropharyngeal cancer are generally younger and 
in better health (less comorbidity). The presence of HPV type 
16 may also be considered a prognostic marker for a higher 
rate of global survival with total recovery, but its predictive 
role has not yet been demonstrated (38,39). Numerous ques-
tions regarding the natural history of HPV infections are still 
under discussion. The ineffectiveness of shared methods for 
identifying molecular markers for HPV infection is one of 
the primary obstacles to their use in clinical practice. For this 
reason, a consensus on the methods to be used for identifying 
high-risk HPV in squamous cell carcinoma in the head and 
neck area is required.
In the present study, QoL, taking into account the pres-
ence of HPV, the type of treatment, the subregion of the 
tonsils vs. the base of the tongue and the disease stage at 
the time of diagnosis, was revealed to not be influenced by 
the aforementioned variables. The data are consistent with 
previous studies, where the role of HPV HR OSCC and 
QoL in general, one year following treatment, was not able 
to be significantly distinguished from the HPV-negative 
role. The tissue samples analyzed in the current study, 
including pathology at an advanced-stage and with associ-
ated long-term patient survival, considered patients from 
5-16 years following their treatment. Therefore, the results 
and the time gap indicate that the only significant variable 
affecting the QoL is the age of the patient.
The results of the present study determined that the 
long-term QoL of patients with HPV-associated advanced-stage 
oropharyngeal squamous cell cancer is as equally compro-
mised as non-HPV-associated oropharyngeal squamous cell 
cancer. It is understood that patients with HPV-associated 
oropharyngeal cancer have a longer life expectancy and, there-
fore, may live longer but also experience the toxic effects of 
the treatment for longer (34). Therefore, developing and imple-
menting a deintensified form of treatment for HPV‑associated 
oropharyngeal cancer is justified.
Future studies may consider a further expansion of the 
sample size, a consensus on the methods used to identify HPV 
and comparisons with the results of various other studies. 
Further studies are required in order to investigate the use of 
deintensified treatments that do not compromise results, but 
are able to reduce the risk of adverse effects and the deteriora-
tion of QoL.
References
 1. Shah JP, Patel SG, Singh B: Jatin Shah's Head and Neck 
Surgery and Oncology. 4th Edition. Elsevier, Philadelphia, PA, 
2012.
 2. Ragin CC and Taioli E: Survival of squamous cell carcinoma of 
the head and neck in relation to human papillomavirus infection: 
Review and meta-analysis. Int J Cancer 121: 1813-1820, 2007.
 3. Bussu F, Sali M, Gallus R, Petrone G, Zannoni GF, Autorino R, 
Dinapoli N, Santangelo R, Vellone VG, Graziani C, et al: Human 
Papillomavirus (HPV) infection in squamous cell carcinomas 
arising from the oropharynx: Detection of HPV DNA and p16 
immunohistochemistry as diagnostic and prognostic indicators-a 
pilot study. Int J Radiation Oncol Biol Phys 89: 1115-1120, 2014.
 4. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines). Head and Neck Cancers. Version 1.2015. National 
Comprehensive Cancer Network, Inc., 2015.
 5. Boscolo-Rizzo P, Tirelli G, Mantovani M, Baggio V, Lupato V, 
Spinato G, Gava A and Da Mosto MC: Non-endemic locoregion-
ally advanced nasopharyngeal carcinoma: Long-term outcome 
after induction plus concurrent chemoradiotherapy in everyday 
clinical practice. Eur Arch Otorhinolaryngol 272: 3491-3498, 
2015.
 6. Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E and 
Conroy T: Quality of life in long-term survivors of oropharynx 
carcinoma. Int J Radiat Oncol Biol Phys 54: 742-51, 2002.
 7. Ausoni S, Boscolo-Rizzo P, Singh B, Da Mosto MC, Spinato G, 
Tirelli G, Spinato R and Azzarello G: Targeting cellular and 
molecular drivers of head and neck squamous cell carcinoma: 
Current options and emerging perspectives. Cancer Metastasis 
Rev 35: 413-426, 2016.
 8. Boscolo Rizzo P, Rampazzo E, Perisinotto E, Piano MA, Giungo S, 
Baboci L, Spinato G, Spinato R, Tirelli G, Da  Mosto MC, et al: 
Telomere shortening in mucosa surrounding the tumor: Biosensor of 
field cancerization and prognostic marker of mucosal failure in head 
and neck squamous cell carcinoma. Oral Oncol 51: 500-507, 2015.
 9. Elrefaey S, Massaro MA, Chiocca S, Chiesa F and Ansarin M: 
HPV in oropharyngeal cancer: The basics to know in clinical 
practice. Acta Otorhinolaryngol Ital 34: 299-309, 2014.
10. Funk GF, Karnell LH and Christensen AJ: Long term 
health-related quality of life in survivors of head and neck cancer. 
Arch Otolaryngol Head Neck Surg 138: 123-133, 2012.
11. Serra A, Caltabiano R, Scalia G, Palmucci S, Di Mauro P 
and Cocuzza S: Papillary squamous cell carcinoma of the 
palatine tonsil: A rare cancer of the head and neck. Acta 
Otorhinolaryngologica Italica 37: 1-5, 2017.
12. Maxwell JH, Mehta V, Wang H, Cunningham D, Duvvuri U, 
Kim S, Johnson JT and Ferris RL: Quality of life in head and 
neck cancer patients: Impact of HPV and primary treatment 
modality. Laryngoscope 124: 1592-1597, 2014.
13. Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL and 
Fang FM: Health related Quality of life in 640 head and neck 
cancer survivors after radiotherapy using EORTC QLQ-C30 and 
QOL-H&N35 questionnaires. BMC Cancer 11: 128, 2011.
14. QoLQuestionnaire-Core 30 (QLQ-C30), EORTC-ITA. http://groups.
eortc.be/qol/why-do-we-need-modules. Accessed March 3, 2015.
15. QoL Questionnaire-Head and Neck 35 (QLQ-H&N35), 
EORTC-ITA. http://groups.eortc.be/qol/why-do-we-need-
modules. Accessed March 3, 2015.
16. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D 
and Bottomley A; On behalf of the EORTC Quality of Life 
Group: The EORTC QLQ-C30 Scoring Manual. 3rd Edition. 
European Organization for Research and Treatment of Cancer, 
Brussels, 2001.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, 
Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, 
de Haes JC, et al: The European Organization for research and 
treatment of cancer QLQ-C30: A quality-of-life instrument for 
use in international clinical trials in oncology. J Natl Cancer 
Inst 85: 365-376, 1993.
18. Baboci L, Holzinger D, Boscolo Rizzo P, Tirelli G, Spinato R, 
Lupato V, Fuson R, Schmitt M, Michel A, Halec G, et al: Low 
prevalence of HPV-driven head and neck squamous cell carcinoma 
in North-East Italy. Papillomavirus Research 2: 133-140, 2016.
ONCOLOGY LETTERS  14:  185-193,  2017 193
19. Schmitt M, Dondog B, Waterboer T and Pawlita M: Homogeneous 
amplification of genital human alpha papillomaviruses by PCR 
using novel broad-spectrum GP5+ and GP6+ primers. J Clin 
Microbiol 46: 1050-1059, 2008.
20. Del Mistro A, Bonaldi L, Bertorelle R, Minucci D, Franzetti M, 
Cattelan A, Bonoldi E, Sposetti R, Torrisi A and Chieco Bianchi L: 
Genital human papillomavirus types in immunocompetent and 
immunodepressed women in northeast Italy: Prevalence and 
cytomorphological correlations. J Low Genit Tract Dis 5: 12-20, 
2001.
21. Carson F and Hladik C: Histotechnology: A Self Instructional 
Text. 3rd edition. American Society for Clinical Pathology Press, 
Hong Kong, 2009.
22. Roche PC and Hsi ED: Immunohistochemistry-Principles and 
Advances. In: Manual of Clinical Laboratory Immunology. 
Rose NR (ed). 6th edition. ASM Press, Washington DC, 2002.
23. Field A, Miles J and Field Z: Discovering Statistics Using R. 
SAGE Publications, London, 2012.
24. Ruxton GD: The unequal variance t-test is an underused alter-
native to Student's t‑test and the Mann‑Whitney U test. Behav 
Ecol 17: 688-690, 2006.
25. Hinni ML and Lott DG (eds): Contemporary Transoral Surgery 
for Primary Head and Neck Cancer. Plural Publishing, San 
Diego, CA, 2014.
26. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, 
Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, et al: 
Deintensification candidate subgroups in human papilloma-
virus-related oropharyngeal cancer according to minimal risk of 
distant metastasis. J Clin Oncol 31: 543-550, 2013.
27. Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM and Li JG: 
Intensity-modulated radiotherapy for oropharyngeal squamous 
cell carcinoma. Laryngoscope 120: 2218-2222, 2010.
28. Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, 
Harari PM, Sanguineti G, Jones CU, Bosch WR and Ang KK: 
Multi-institutional trial of accelerated hypofractionated 
intensity-modulated radiation therapy for early-stage oropha-
ryngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76: 
1333-1338, 2010.
29. Yong JH, Beca J, O'Sullivan B, Huang SH, McGowan T, Warde P 
and Hoch JS: Cost-effectiveness of intensity-modulated radio-
therapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol) 24: 
532-538, 2012.
30. Kurzweg T, Möckelmann N, Laban S and Knecht R: Current 
treatment options for recurrent or metastatic head neck cancer: A 
post‑ASCO 2011 update and review of last year's literature. Eur 
Arch Otorhinolaryngol 269: 2157-2167, 2012.
31. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ and García-Sáenz JA, 
Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative 
Group (TTCC): Phase II study of the combination of cetuximab 
and weekly paclitaxel in the first‑line treatment of patients with 
recurrent and/or metastatic squamous cell carcinoma of head and 
neck. Ann Oncol 23: 1016-1022, 2012.
32. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, 
O'Sullivan B, Waldron J, Cummings B, Kim J, et al: Comparative 
prognostic value of HPV16 E6 mRNA compared with in situ 
hybridization for human oropharyngeal squamous carcinoma. 
J Clin Oncol 27: 6213-6221, 2009.
33. Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, 
Michel A, Schmitt M, Spinato G, Bussani R, Alemany L, et al: 
Evidence of the causal role of human papillomavirus type 58 in 
an oropharyngeal carcinoma. Virol J 10: 334, 2013.
34. D'Souza G and Dempsey A: The role of HPV in head and neck 
cancer and review of the HPV vaccine. Prev Med 53 (Suppl 1): 
S5-S11, 2011.
35. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, 
Orlandi E, Palazzi M and Olmi P: Oropharyngeal squamous 
cell carcinoma treated with radiotherapy or radiochemotherapy: 
Prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol 
Phys 75: 1053-1059, 2009.
36. Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, 
Sartor G, Politi D, Trovò MG and Barzan L: Radiotherapy for 
patients with early-stage glottic carcinoma: Univariate and multi-
variate analyses in a group of consecutive, unselected patients. 
Cancer 98: 765-772, 2003.
37. Da Mosto MC, Lupato V, Romeo S, Spinato G, Addonisio G, 
Baggio V, Gava A and Boscolo-Rizzo P: Is neck dissection 
necessary after induction plus concurrent chemoradiotherapy in 
complete responder head and neck cancer patients with pretherapy 
advanced nodal disease? Ann Surg Oncol 20: 250-256, 2013.
38. Pignon JP, Bourhis J, Domenge C and Designé L: Chemotherapy 
added to locoregional treatment for head and neck squamous-cell 
carcinoma: Three meta-analyses of updated individual 
data. MACH-NC Collaborative Group. Meta-Analysis of 
Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955, 
2000.
39. Sharma A, Méndez E, Yueh B, Lohavanichbutr P, Houck J, 
Doody DR, Futran ND, Upton MP, Schwartz SM and Chen C: 
Human papillomavirus-positive oral cavity and oropharyngeal 
cancer patients do not have better quality-of-life trajectories. 
Otolaryngol Head Neck Surg 146: 739-745, 2012.
